FINWIRES · TerminalLIVE
FINWIRES

研究快訊:CFRA維持對Biogen Inc.股票的買入評等。

By

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:我們維持對BIIB的目標價為236美元,相當於我們2027年每股盈餘預期值的13.8倍,低於BIIB過去五年14.1倍的平均預期本益比。我們將2026年每股盈餘預期值從16.14美元下調至15.24美元,以反映收購智慧財產權和研發業務的影響。我們維持對2027年每股盈餘預期值17.16美元不變。 BIIB 2026年開局強勁,銷售額達25億美元,調整後每股收益為3.57美元。我們認為,由於成長型產品組合年增12%,該公司在經歷了多年的下滑後成功穩定。 我們認為,在分析師電話會議上,管理階層提出了一個清晰的策略願景,其核心是即將完成的以56億美元收購Apellis的交易。該交易預計將於第二季完成,透過新增Syfovre和Empaveli兩項商業化資產,BIIB可望轉型為成長型公司。我們認為,Apellis的收購可以彌補公司在2028年後期研發管線成熟之前的收入缺口。透過此次收購,BIIB還將獲得腎臟病學領域的專業知識和完善的基礎設施,這將有助於其關鍵資產Felzartamab的成功上市。

Related Articles

Research

Research Alert: F: Q1 Well Ahead Of Expectations, But Revised Guidance Raises Questions

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ford (F) posted Q1 adjusted EPS of $0.66 vs. $0.14, well ahead of the $0.19 consensus. The beat was driven by stronger-than-expected sales and margins, as automotive revenue rose 6.4% to $39.82B ($1.0B ahead of consensus) and adjusted EBIT margin expanded 560 bps to 8.1%. Results included a $1.3B one-time IEEPA tariff benefit reflecting amounts paid between March 2025 and February 2026. Ford raised full-year adjusted EBIT guidance to $8.5B-$10.5B from $8.0B-$10.0B, the midpoint of which is well above the $8.87B consensus. Ford's guidance for 2026 adjusted FCF and capex was unchanged at $5B-$6B and $9.5B-$10.5B, respectively. Shares initially surged higher on the beat and increased guidance in after-hours trading, but quickly gave back the gains, as the release begged the question of why Ford didn't raise full-year earnings guidance by an even greater amount in light of the $1.3B IEEPA tariff benefit. It appears to be mainly due to the company's expectation of a greater commodity cost headwind in 2026 (~$2B).

$F
Research

Research Alert: Meta Guides Q2 In Line With Views; Tweaks Capex Spend Higher

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:META posted Q1 revenue growth of 33% to $56.31B, beating our 31% forecast, while diluted EPS of $10.44 (+62% Y/Y) and adjusted EPS of $7.31 exceeded consensus of $7.08. Strong advertising fundamentals drove the beat, with ad impressions growing 19% and average price per ad increasing 12%, demonstrating both reach expansion and pricing power across platforms. The robust performance reflects disciplined operating leverage with margins holding steady at 41% despite 35% cost increases, supported by strong cash generation of $32.23B in operating cash flow. Management guided Q2 revenue of $58B-$61B (25% growth), in line with expectations, while maintaining full-year expense guidance of $162B-169B. We note the modest capex guidance increase to $125B-$145B from $115B-$135B, reflecting higher component pricing and data center costs. Reality Labs losses of $4.03B showed improvement from the prior year's $4.21B, suggesting the segment may be approaching peak losses in our view.

$META
Research

Research Alert: Equinix Q1: Revenue And Affo Miss, Large Ai Deals Fuel $378m Bookings Growth

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EQIX reported Q1 total revenue of $2.44B, up 9.8% Y/Y from $2.23B in the prior year, though falling $66M short of consensus estimates. Colocation revenue grew 12.0% to $1.73B, while Interconnection revenue increased 13.5% to $446M, with Managed Infrastructure remaining flat at $115M and non-recurring revenue declining 18.1% to $113M. The company demonstrated strong underlying momentum with Q1 annualized bookings reaching $378M and record annualized presales of $140M, with approximately 60% of the largest deals being AI-related, highlighting EQIX's strategic positioning to capitalize on the AI megatrend driving data center demand. We expect interconnection revenue growth to accelerate Q/Q in 2026 from the current 13.5% Y/Y pace, a trend that has shown consistent improvement for five consecutive quarters. In our view, this trend positions EQIX well for continued expansion in this high-margin segment as enterprise AI adoption broadens across industries.

$EQIX